XRF Scientific (ASX:XRF) YoY EBITDA Growth: 5.36% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:XRF XRF Scientific Ltd ASX:XRF
92 GF Score
Price A$1.83
GF Value A$1.67
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is XRF Scientific YoY EBITDA Growth?

XRF Scientific ASX:XRF +1.39% 92 YoY EBITDA Growth is 5.36% as of Dec. 2025. GuruFocus rates ASX:XRF with a GF Score™ of 92/100 and a GF Value™ of A$1.67 (Fairly Valued). The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. XRF Scientific's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 5.36%.

XRF Scientific's EBITDA per Share for the six months ended in Dec. 2025 was A$0.06.

XRF Scientific YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for XRF Scientific's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XRF Scientific YoY EBITDA Growth Chart

XRF Scientific Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.36 16.67 38.57 14.43 6.31

XRF Scientific Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.77 18.00 5.66 5.08 5.36
ASX:XRF
92GF Score
XRF Scientific Ltd ASX:XRF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XRF Scientific YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

XRF Scientific's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(0.118-0.111)/ | 0.111 |
=6.31 %

XRF Scientific's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.059-0.056)/ | 0.056 |
=5.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 5.36% mean?
XRF Scientific (ASX:XRF) has a YoY EBITDA Growth of 5.36% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for XRF Scientific and its competitors.
Is XRF Scientific's YoY EBITDA Growth too high?
XRF Scientific's current YoY EBITDA Growth is 5.36%. Overall, XRF Scientific has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does XRF Scientific's YoY EBITDA Growth compare to MMM and HON?
XRF Scientific's YoY EBITDA Growth of 5.36% can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Conglomerates company?
A good YoY EBITDA Growth depends on the Conglomerates industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for XRF Scientific and its competitors. XRF Scientific's current YoY EBITDA Growth is 5.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XRF Scientific stock overvalued right now?
Based on GuruFocus' analysis, XRF Scientific (ASX:XRF) is currently considered Fairly Valued. The stock's GF Value™ is A$1.67, compared to a current price of A$1.83 — trading 9.6% above its estimated fair value. The current YoY EBITDA Growth is 5.36%. XRF Scientific's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For XRF Scientific (ASX:XRF), the current YoY EBITDA Growth is 5.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XRF Scientific (ASX:XRF) Overvalued in 2026?

Based on GuruFocus' analysis, XRF Scientific stock appears to be overvalued. The current stock price of A$1.83 is trading 9.6% above its estimated GF Value™ of A$1.67. GuruFocus considers XRF Scientific to be Fairly Valued.

Key valuation signals for ASX:XRF:

  • YoY EBITDA Growth: 5.36%
  • GF Value™: A$1.67 vs. price of A$1.83 (9.6% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the ASX:XRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XRF Scientific Business Description

Address 86 Guthrie Street, Osborne Park, Perth, WA, AUS, 6017
XRF Scientific Ltd is engaged in the business of manufacturing and marketing precious metal products, specialized chemicals and instruments for the scientific, analytical and mining industries. It operates through the following segments: Capital Equipment, Precious Metals, and Consumables. The company generates maximum revenue from the Capital Equipment segment that Manufactures sample preparation products and analytical instruments. Geographically, it derives a majority of revenue from Australia and also has a presence in Canada and Europe. Some of its product includes Electric Fusion Machines; Fusion Flux; Crushing and Pulverising, platinum lab ware and others.
92GF Score

Get the complete analysis for ASX:XRF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.83
Price
A$1.67
GF Value